Glycopyrrolate

Leading Pharma, Llc
Human Prescription Drug
NDC 69315-139

Glycopyrrolate is a human prescription drug labeled by 'Leading Pharma, Llc'. National Drug Code (NDC) number for Glycopyrrolate is 69315-139. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Glycopyrrolate drug includes Glycopyrrolate - 1 mg/1 . The currest status of Glycopyrrolate drug is Active.

Drug Information:

Drug NDC:	69315-139
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Glycopyrrolate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Glycopyrrolate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Leading Pharma, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	GLYCOPYRROLATE - 1 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	22 Sep, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	26 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number:	ANDA090195
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date:	31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	Leading Pharma, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:	197738 197739
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:	Yes
Whether or not the drug has been repackaged for distribution.
UPC:	0369315139011 0369315140017
UPC stands for Universal Product Code.
UNII:	V92SO9WP2I
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:	Anticholinergic [EPC] Cholinergic Antagonists [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
69315-139-01	100 TABLET in 1 BOTTLE (69315-139-01)	22 Sep, 2018	N/A	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Product Elements:

Glycopyrrolate glycopyrrolate glycopyrrolate glycopyrronium povidone anhydrous lactose anhydrous dibasic calcium phosphate magnesium stearate sodium starch glycolate type a potato ep;139 glycopyrrolate glycopyrrolate glycopyrrolate glycopyrronium anhydrous dibasic calcium phosphate magnesium stearate anhydrous lactose povidone sodium starch glycolate type a potato ep;140

Drug Interactions:

Drug interactions there are no known drug interactions.

Indications and Usage:

Indications for use as adjunctive therapy in the treatment of peptic ulcer.

Warnings:

Warnings in the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of glycopyrrolate tablet, usp. diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. in this instance treatment with this drug would be inappropriate and possibly harmful. glycopyrrolate tablet, usp may produce drowsiness and blurred vision. in this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug. theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

Dosage and Administration:

Dosage and administration the dosage of glycopyrrolate tablet, usp should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. the presently recommended maximum daily dosage of glycopyrrolate is 8 mg. glycopyrrolate tablet, usp 1 mg. the recommended initial dosage of glycopyrrolate tablet, usp for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). some patients may require two tablets at bedtime to assure overnight control of symptoms. for maintenance, a dosage of one tablet twice a day is frequently adequate. glycopyrrolate tablet, usp 2 mg. the recommended dosage of glycopyrrolate tablet, usp for adults is one tablet two or three times daily at equally spaced intervals. glycopyrrolate tablet, usp are not recommended for use in pediatric patients under the age of 12 years.

Contraindications:

Contraindications glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablet, usp are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

Adverse Reactions:

Adverse reactions anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations. glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. for this reason the occurrence of cns related side effects is lower, in comparison to their incidence following administra Read more...

tion of anticholinergics which are chemically tertiary amines that can cross this barrier readily. call your doctor for medical advice about side effects. you may report side effects to the fda at 1-800-fda-1088 or leading pharma, llc at 1-844-740-7500.

Drug Interactions:

Drug interactions there are no known drug interactions.

Use in Pregnancy:

Pregnancy the safety of this drug during pregnancy has not been established. the use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. such experience has revealed no reports of teratogenic or other fetus-damaging potential. no controlled studies to establish the safety of the drug in pregnancy have been performed.

Pediatric Use:

Pediatric use since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

Overdosage:

Overdosage the symptoms of overdosage of glycopyrrolate tablet, usp are peripheral in nature rather than central. to guard against further absorption of the drugâuse gastric lavage, cathartics and/or enemas. to combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.)âutilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate. to combat hypotensionâuse pressor amines (norepinephrine, metaraminol) i.v.; and supportive care. to combat respiratory depressionâadminister oxygen; utilize a respiratory stimulant such as dopram Â® i.v.; artificial respiration.

Description:

Description glycopyrrolate tablet, usp contain the synthetic anticholinergic, glycopyrrolate. glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide. its empirical formula is c 19 h 28 brno 3 , its molecular weight is 398.33, and its structural formula is: each 1 mg tablet contains: glycopyrrolate usp, 1 mg each 2 mg tablet contains: glycopyrrolate usp, 2 mg inactive ingredients: dibasic calcium phosphate, lactose, magnesium stearate, povidone, and sodium starch glycolate chemical structure

Clinical Pharmacology:

Actions glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. these peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. the highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and sco Read more...

polamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

How Supplied:

How supplied glycopyrrolate tablet, usp 1 mg are bisected, compressed white, round tablets debossed âepâ above the bisect and â139â below the bisect on one side of the tablet, and plain on the other side. available in bottles of 100 (ndc 69315-139-01) glycopyrrolate tablet, usp 2 mg are bisected, compressed white, round tablets debossed âepâ above the bisect and â140â below the bisect on one side of the tablet, and plain on the other side. available in bottles of 100 (ndc 69315-140-01).

Package Label Principal Display Panel:

Package label.principal display panel ndc 69315-139-01 1 mg: bottle of 100 tablets ndc 69315-140-01 2 mg: bottle of 100 tablets glycopyrrolate 1mg 100tabs glycopyrrolate 2mg 100tabs

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.